52
Participants
Start Date
April 6, 2021
Primary Completion Date
January 19, 2022
Study Completion Date
April 21, 2022
Spesolimab - solution for infusion
Solution for infusion
Placebo matching spesolimab - solution for infusion
Solution for infusion
Spesolimab- solution for injection
Solution for injection
Placebo matching to spesolimab- solution for injection
Solution for injection
ULB Hopital Erasme, Brussels
Holdsworth House Medical Practice, Sydney
Royal Melbourne Hospital, Parkville
Nordlandssykehuset HF, Bodø, Bodø
University of Pittsburgh Medical Center, Pittsburgh
HOP Larrey, Toulouse
Non-Public Health Care Facility LABDERM, Ossy
Katholisches Klinikum Bochum gGmbH, Bochum
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
CLI Reims Bezannes, Bezannes
Mayo Clinic, Rochester, Rochester
Azienda Ospedaliera Universitaria Pisana, Pisa
Ospedali Riuniti di Ancona, Ancona
Universitätsklinikum Frankfurt, Frankfurt am Main
HOP Edouard Herriot, Lyon
Unity Clinical Research, Oklahoma City
Dermatology Research Associates, Los Angeles
Dr. S. K. Siddha Medicine Professional Corporation, Newmarket
University Hospital Ostrava, Ostrava
Städtisches Klinikum Dessau, Dessau
Erasmus Medisch Centrum, Rotterdam
Haukeland Universitetssykehus, Bergen
Oslo Universitetssykehus HF, Rikshospitalet, Oslo
Cityclinic Medical and Psychological Clinic Matusiak Partnership, Wroclaw
Hospital Santa Creu i Sant Pau, Barcelona
Lead Sponsor
Boehringer Ingelheim
INDUSTRY